Dana-Farber Cancer Institute shared a post on LinkedIn:
“We are proud to announce that both our adult and pediatric stem cell/bone marrow transplant programs have achieved a +1 score in the 2025 CIBMTR (Center for International Blood & Marrow Transplant Research) Transplant Center-Specific Survival Report. This prestigious score, the highest possible, signifies that our programs have surpassed the expected one-year survival rate for allogeneic or donor stem cell transplants in the U.S.
This marks the sixth consecutive year that Dana-Farber Brigham Cancer Center’s adult stem cell transplant program has earned a +1 score. Notably, among large centers performing over 310 transplants in a three-year period, ours is the only large-volume center to achieve this distinction.
It is the second year in a row that our pediatric stem cell transplant program achieved the +1 score. Dana-Farber/Boston Children’s Cancer and Blood Disorders Center is the only dedicated pediatric program to achieve this score.
The CIBMTR report analyzed 26,422 allogeneic stem cell/bone marrow transplants across 176 U.S. centers. Our adult and pediatric programs are two of only eight centers nationwide to exceed the expected one-year survival rate for donor stem cell transplants.
Thank you to our dedicated team and partners for their unwavering commitment to excellence and patient care. Together, we continue to make a difference for our patients.
More posts featuring Dana-Farber Cancer Institute.